Trial Profile

Acute Hemodynamic Effects of Riociguat (BAY63-2521) in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure: A Randomized, Double-blind, Placebo-controlled, Single-dose Study in Three Ascending Dose Cohorts

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Sep 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Riociguat (Primary)
Indications Diastolic heart failure; Left ventricular dysfunction; Pulmonary hypertension
Focus Therapeutic Use
Acronyms DILATE; DILATE-1
Sponsors Bayer

27 Sep 2013 Primary endpoint 'Pulmonary-artery-pressure' has not been met.
27 Sep 2013 New trial record
04 Sep 2013 Results presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com